Alpine Global Management’s NovoCure NVCR Stock Holding History

Alpine Global Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,285	Closed	-$772K	–	634
2021 Q4	$772K	Buy	+10,285	New	+$1.03M	0.11%	191
2019 Q4	–	Sell	-3,789	Closed	-$283K	–	437
2019 Q3	$283K	Buy	+3,789	New	+$303K	0.07%	53

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpine Global Management's NVCR Position: Q1 2022 in Review

Alpine Global Management sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 10,285 shares — an estimated $772K sold.

Alpine Global Management first reported a position in NVCR in Q3 2019 and held it in 2 quarters. The position peaked at $772K in Q4 2021. 308 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

Alpine Global Management reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
Alpine Global Management sold 10,285 NovoCure shares in Q1 2022, an estimated $772K.
Alpine Global Management first reported a position in NovoCure in Q3 2019 and held it in 2 quarters.
Alpine Global Management's NovoCure position peaked at $772K in Q4 2021.
308 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.